The group plays down upcoming interim analysis, but still hopes for accelerated approval.

The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.

The company dribbles out more data on IMA203, and the numbers head in the right direction.

Keyvibe-010 fails, but not for the reason you might have expected.

Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.

Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.